Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Liv Path > Micro - Management, Hepatitis Serology, CNS Infections and Congenital/Childhood Infections > Flashcards

Micro - Management, Hepatitis Serology, CNS Infections and Congenital/Childhood Infections Flashcards

1
Q

ABX inhibiting cell wall synthesis

A

BCG

Beta lactams - penicillin, cephalosporins
Carbapenems (these are also B lactams) - meropenem
Glycopeptides - vancomycin, teicoplanin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ABX inhibiting protein synthesis

A

TAM

Tetracyclines - tetracycline, doxycycline
Aminoglycosides - gentamycin
Macrolies - erythromycin, clarithromycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ABX inhibiting nucleic acid synthesis

A

Quinolones - ciprofloxacin, ofloxacin

Other - metronidazole, trimethoprim, rifampicin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ABX inhibiting folate synthesis

A

Sulphonamides - trimethoprim?, septrin

Diaminopyrimidines - trimethoprim

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Amoxicillin

A

Beta-Lactams: Penicillins (-cillin)
Cover Gram +ve mainly

Broad-spectrum, covers some Gram –ve (like Haemophilus, enterococci) –> first-line for pneumonia

broken down by β-lactamase produced by S. aureus and many Gram negative organisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Piperacillin

A

Beta-Lactams: Penicillins (-cillin)
Cover Gram +ve mainly

Broad-spectrum, covers some Gram –ve (like Haemophilus) –> first-line for pneumonia. COVERS PSEUDOMONAS and other non-enteric gram -ves

broken down by β-lactamase produced by S. aureus and many Gram negative organisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Ampicillin

A

Beta-Lactams: Penicillins (-cillin)
Cover Gram +ve mainly

Listeria listeria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Flucloxacillin

A

Beta-Lactams: Penicillins (-cillin)
Cover Gram +ve mainly

Staph aureus (skin infections)

Less active than penicillin but stable to B-lactamase produced by staph a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Benzylpenicillin

A

Beta-Lactams: Penicillins (-cillin)
Cover Gram +ve mainly

Group A strep (“sore throat”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Penicillis are often used with

A

beta-lactamase inhibitors:
Co-amoxiclav = amoxicillin + clavulanic acid
Tazocin = piperacillin + tazobactam

Protect penicillins from enzymatic breakdown and increase coverage to include S. aureus, Gram negatives and anaerobes. V useful for HAI.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What to use if someone is penicillin allergic

A

Just rash: use cephalosporin (5-10% cross-reactivity)

Anaphylaxis: doxycycline for pneumonia, erythromycin for impetigo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

1st Generation Cephalosporins (Beta-Lactams)

A

(cefalexin): Gram +ve but not –ve

Cefuroxime is 2nd gen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

3rd generation Cephalosporins (Beta-Lactams)

A

(cefotaxime, ceftriaxone, ceftazidime): Gram –ve but not +ve

Used in hospital acquired pneumonia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cephalosporin management of pseudomonas

A

Ceftazidime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cephalosporin management of meningitis

A

IV ceftriazone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Carbapenems - uses

A

For severe infections, when beta-lactams would not work

Extended-Spectrum Beta-Lactamases = resistant to beta-lactams

Carbapenemase enzymes becoming more widespread. Multi drug resistant Acinetobacter and Klebsiella species.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Meropenem

A

Sepsis of unknown origin, severe abdominal infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Glycopeptides

A

Gram +ve only

MRSA = vancomycin (IV only)
Oral vancomycin can be used to treat serious C. difficile infection

Slowly bactericidal
Nephrotoxic – hence important to monitor drug levels to prevent accumulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Aminoglycosides (end in –cin)

A
  • Rapid, concentration-dependent bactericidal action
  • Require specific transport mechanisms to enter cells
  • Ototoxic & nephrotoxic, therefore must monitor levels
  • Synergistic combination with B-lactams
  • No activity vs. anaerobes
    Gram -ve only
    Pseudomonas = gentamycin, tobramycin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Tetracycline (end in –cycline)

A
  • Broad-spectrum agents with activity against intracellular pathogens (e.g. chlamydiae, rickettsiae & mycoplasmas) as well as most conventional bacteria
  • Bacteriostatic (stops reproduction)
  • Widespread resistance limits usefulness to certain defined situations
  • Do not give to children or pregnant women
  • Main side-effect: Light-sensitive rash

Intracellular bacteria
Chlamydia = doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Macrolides (end in –mycin)

A

Bacteriostatic

Gram +ve –> substitute for penicillin if allergic (vs staph/strep).

Also active against Campylobacter sp and Legionella. Pneumophila

Atypical pneumonia = add clarithromycin to amoxicillin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Oxazolidinones (end in –zolid)

A

Excellent for Gram +ve (not active against most -ve)

Vancomycin-Resistant Enterococci (VRE) = linezolid

Is expensive, may cause thrombocytopoenia and should be used only with consultant Micro/ID approval. Can cause optic neuritis –> don’t tend to use over long periods (more than 4 weeks).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Nitroimidazole (end in –azole)

A

Anaerobic bacteria

C. Diff = metronidazole

Under anaerobic conditions, an active intermediate is produced which causes DNA strand breakage

Rapidly bactericidal

Active against anaerobic bacteria and protozoa (e.g. Giardia)

Nitrofurans are related compounds: nitrofurantoin is useful for treating simple UTIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Rx - herpes simplex & HSV encephalitis

A

HSV:
Aciclovir
2nd line = foscarnet

HSV encephalitis:
On clinical suspicion- Start empiric treatment immediately without waiting for test results
iv ACV 10mg/kg tds
If confirmed, treat for 14 - 21 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Rx - varicella zoster

A

Acyclovir

Indications for Rx:

  • Chickenpox in adults (risk of complication: pneumonitis)
  • Zoster in adults >50 (risk of complication: post-herpetic neuralgia)
  • 1o infection or reactivation in the immunocompromised
  • Neonatal chickenpox
  • If there is an increased risk of complications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Rx - cytomegalovirus (CMV) = immunocompromised

A

Ganciclovir (IV or vGCV = oral prodrug) Guanosine analogue - inhibits viral DNA synthesis.

Primary infection:

  • Latency in blood monocytes and dendritic cells
  • Reactivation (eg following immunosuppression)

Asymptomatic shedding in saliva, urine, semen and cervical secretions.

MAJOR pathogen in the immunocompromised (including solid organ and bone marrow transplant patients) – causes marrow suppression, retinitis, pneumonitis, hepatitis, colitis, encephalitis…

Can give:
Ganciclovir(GCV) iv. SEs: bone marrow, renal and hepatic toxicity. Contraindicated in BM suppression (neutropenia).

Valganciclovir (VGC) po

Foscarnet (FOS) iv / intravitreal - Non-competitive inhibitor of viral DNA, polymerase. Use when GCV contraindicated ie neutropenic patients (eg pre-engraftment post-BMT); GCV-resistant CMV; CMV retinitis (intravitreal implants). Nephrotixic.

Cidofovir (CDV) iv - Nucleotide (cytidine) analogue (Competitive inhibitor of viral DNA synthesis). Nephrotoxic - Require hydration + probenicid.

Also maribavir (inhibits viral kinase (UL97), effective in vitro against GCV resistant CMV), letermovir (CMV DNA terminase* inhibitor) - CMV prophylaxis in CMV+  SCT recipients.
Give Ganiciclovir with IVIG for CMV pneumonitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Rx - EBV (infectious mononucleosis, infects B cells- life-long)

A

Rituximab (anti-CD20) for post-transplant lymphoproliferative disease (reactivation of EBV with immunosuppression)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Rx - Influenza (A&B)

A

Oseltamivir (“Tamiflu”)
Neuraminidase inhibitor

Inpatients:
Indicated for all patients admitted to hospital due to influenza virus-related respiratory disease

Indicated in the community if all 3 apply (NICE guidance):

  • National surveillance indicates influenza is circulating
  • Patient is in a ‘risk-group’ *
  • Within 48 hours of symptom onset (36 hours for zanamivir)

Peramivir - Neuraminidase inhibitor licensed in US, but also available in UK. H275Y mutation confers reduced susceptibility –> avoid use with oseltamivir resistance

Baloxavir merboxil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Rx - Respiratory Syncytial Virus (RSV) = in young kids

A

Treat: ribavirin (Guanosine analogue, PO)
Prevent: palivizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Rx - Adenovirus = after bone-marrow transplant

A

Cidofovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Herd immunity threshold calculation

A

Herd Immunity threshold = 1 – 1/R0

R0= the average number of people that one sick person will infect. To eliminate a disease the effective R0 needs to be <1.

Herd immunity threshold = percentage of fully immune individuals required to stop the spread of disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Live attenuated vaccine

A

Stimulates all aspects of the immune system e.g. MMR, yellow fever
T cell response important in destroying infected cells.

Advantages:
Single dose often sufficient to induce long-lasting immunity
May stimulate response to multiple protective antigens
Strong immune response evoked
Local and systemic immunity produced – particularly important for infections where CMI plays an important role. Activation of all components of immune system

Disadvantages
Potential to revert to virulence
Can cause illness directly
Contraindicated in immunosuppressed patients
Interference by viruses or vaccines and passive antibody
Poor stability
Potential for contamination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Inactivated vaccine

A

Need adjuvant to boost immune response e.g. influenza, polio

Whole microorganism destroyed by heat, chemicals, radiation or antibiotics (e.g. Influenza, cholera, polio)

Advantages:
Stable
Constituents clearly defined
Unable to cause the infection

Disadvantages:
Need several doses
Local reactions commn 
Adjuvant needed
Shorter lasting immunity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Subunit vaccine

A

Need adjuvant to boost immune response e.g. Hep B, HPV

Protein component of the microorganisms or synthetic virus like particles.
Lacking viral genetic material and unable to replicate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Viral vector vaccine

A

Type of cloning –> grow viral proteins which induce immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

DNA vaccine

A

Type of cloning –> inject genes encoding viral antigens –> host cells make the antigens (and therefore induce B and T cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Virus-like particles vaccine

A

Type of cloning –> virus which doe snot replicate (so you can give the intact virus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Toxoid vaccine

A

Inactivated toxin e.g. tetanus, diptheria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Conjugate vaccine

A

Poorly immunogenic antigens and highly immunogenic adjuvant e.g. haemophilius influenza type B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Heterotypic vaccine

A

Pathogens which do not cause disease in humans e.g. BCG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Hep A Features

A

Faecal-oral
Acute, never chronic
“Fever, malaise, raised ALT in someone coming from India”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Hep B Features

A

DNA virus, same transmission modes as HIV (more likely sex than C)
Presents like Hep A, but can cause liver cancer and cirrhosis
Treatment: interferon-a and tenofovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Hep C Features

A

RNA virus, same transmission modes as HIV (more likely blood than B) (“transfusion long time ago”)
80% become chronic –> 25% cirrhosis
PCR shows HCV RNA = acute; anti-HCV antibodies = chronic
Treatment: antiviral combination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Hep D Features

A

Need Hep B to get Hep D!

Treatment: interferon-a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Hep E Features

A

Like Hep A, but from Indochina, can be chronic and spread via pigs!
Treatment: ribavirin

46
Q

Hep B Serology

A
  • Surface antigen (HBsAg): current infection (Hep B vaccine is literally just surface antigen)
  • “e” antigen (HBeAg): high infectivity
  • Core antibody (anti-HBc): previous infection
    IgM core antibody: acute
    IgG core antibody: chronic

Surface antibody (anti-HBs): immune
Core and surface antibody: immune due to infection
Only surface antibody: immune due to vaccination

e antibody (anti-HBe): previous acute phase reaction, when virus replicated lots – not as important

47
Q

Hep B Screening

A

Surface antigen = current infection

Core antibody = previous infection

48
Q

If both screening tests for Hep B +ve

A

e antigen = infectivity

Hep B DNA = viral load

49
Q

Meningitis Causes - General

A

Acute - bacterial
Chronic - TB, cryptococcus (immunocomp)
Aseptic - viral (most common, often preceding flu)

50
Q

Acute meningitis - Neisseria meningitidis

A

Non-blanching rash

51
Q

Acute meningitis - Streptococcus pneumoniae

A

Biphasic = young and old

52
Q

Acute meningitis - Listeria

A

“Tumbling motility”

In eggs/cheese/mayo

53
Q

Acute meningitis - Group B strep

A

Neonatal meningitis

54
Q

India ink stain - CSF

A

India ink stain (circles are yeast)

= cryptococcus

55
Q

Meningitis - Rx (adult)

A

Ceftriaxone - 2g IV bd

If >50y/o or immunocompromised add amoxicillin 2g IV 4 hourly (covers listeria)

56
Q

Meningo-encephalitis - Rx (adult)

A

Acyclovir 10mg/kg IV tds (covers herpes)

Ceftriaxone 2g IV bd

If >50y/o or immunocompromised add amoxicillin 2g IV 4 hourly (covers listeria)

57
Q

B lactams MOA

A
  • Inactivate the enzymes that are involved in the terminal stages of cell wall synthesis (transpeptidases also known as penicillin binding proteins) – β-lactam is a structural analogue of the enzyme substrate
  • Bactericidal
  • Active against rapidly-dividing bacteria
  • Ineffective against bacteria that lack peptidoglycan cell walls (e.g. Mycoplasma or Chlamydia)

Active against rapidly dividing bacteria. Inhibit new cell synthesis –> weak daughter cells –> osmotic lysis. Do not damage the walls of the original cells. No activity if cells aren’t dividing.

58
Q

Penicillin

A

Gram positive organisms, Streptococci, Clostridia; broken down by an enzyme (β-lactamase) produced by S. aureus

59
Q

Key Features of B lactams

A

Relatively non-toxic

Renally excreted (so ↓dose if renal impairment)

Short half life- most prescribed multiple times per day (need to maintain level in blood for bacterial death)

Will not cross intact blood-brain barrier (will cross inflamed meninges, good for meningitis)

Cross-allergenic (penicillins approx 10% cross-reactivity with cephalosporins or carbapenems)

60
Q

Chloramphenicol

A

used more now due to the rise of resistance - can be used for CAP, meningitis when allergic to cephalasporins

  • Bacteriostatic
  • Very broad antibacterial activity
  • Rarely used (apart from eye preparations and special indications) because risk of aplastic anaemia (1/25,000 – 1/45,000 patients) and grey baby syndrome in neonates because of an inability to metabolise the drug
61
Q

Aminoglycosides MOA

A

Bind to amino-acyl site of the 30S ribosomal subunit - prevent elongation of the polypeptide chain –> cause misreading of the codons along the mRNA

62
Q

Glycopeptides MOA

A

Stops formation of peptide cross links and glycocidic bonds –> weakened cell wall –> cells then lyse. Inhibits cell division.

63
Q

Tetracylines MOA

A

Reversibly bind to the ribosomal 30S subunit

Prevent binding of aminoacyl-tRNA to the ribosomal acceptor site, so inhibiting protein synthesis.

64
Q

Macrolides MOA

A

Bind to the 50s subunit of the ribosome –> interfere with translocation –> stimulate dissociation of peptidyl-tRNA

In v severe cellulitis or necrotizing fasciitis Clarthromycin prevents protein synthesis and so release of bacterial toxins.

65
Q

Chloramphenicol MOA

A

Chloramphenicol binds to the peptidyl transferase of the 50S ribosomal subunit and inhibits the formation of peptide bonds during translation

66
Q

Oxazolidinones MOA

A

Binds to the 23S component of the 50S subunit to prevent the formation of a functional 70S initiation complex (required for the translation process to occur).

67
Q

Quinolones

A

e.g. Ciprofloxacin, Levofloxacin, Moxifloxacin

Act on a-subunit of DNA gyrase predominantly, but, together with other antibacterial actions, are essentially bactericidal

Broad antibacterial activity, especially vs Gram –ve organisms, including Pseudomonas aeruginosa

Newer agents (e.g. levofloxacin, moxifloxacin) increased activity vs G +ves (pneumococcus) and intracellular bacteria, e.g. Chlamydia spp

Well absorbed following oral administration

Use for UTIs, pneumonia, atypical pneumonia & bacterial gastroenteritis.

Be wary of use in unstable pts - hypotensive, tachycardic etc.
25% e colis now resistant to them, almost all salmonella typhi resistant.
Big problems with causing c diff infection and tendonitis.

68
Q

Rifamycins

A

e.g. rifampicin & rifabutin

Inhibitors of RNA synthesis.

69
Q

Rifampicin

A
  • Inhibits protein synthesis by binding to DNA-dependent RNA polymerase thereby inhibiting initiation
  • Bactericidal
  • Active against certain bacteria, including Mycobacteria & Chlamydiae
  • Monitor LFTs
  • Beware of interactions with other drugs that are metabolised in the liver (e.g oral contraceptives)
  • May turn urine (& contact lenses) orange

Except for short-term prophylaxis (vs. meningococcol infection) you should NEVER use as single agent because resistance develops rapidly. Resistance is due to chromosomal mutation. This causes a single amino acid change in the ß subunit of RNA polymerase which then fails to bind Rifampicin.

70
Q

Daptomycin

A

Cell membrane toxin

Cyclic lipopeptide with activity limited to G+ve pathogens. It is a recently-licenced antibiotic likely to be used for treating MRSA and VRE infections as an alternative to linezolid and Synercid.

71
Q

Colistin

A

Cell Membrane Toxin

polymyxin antibiotic that is active against Gram negative organisms, including Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella. pneumoniae. It is not absorbed by mouth. It is nephrotoxic and should be reserved for use against multi-resistant organisms. Attacks outer membrane so can allow other abxs to get in.

72
Q

Sulphonamides and Diaminopyrimidines

A

Act indirectly on DNA through interference with folic acid metabolism

Synergistic action between the two drug classes because they act on sequential stages in the same pathway

Sulphonamide resistance is common, but the combination of sulphamethoxazole+trimethoprim (Co-trimoxazole) is a valuable antimicrobial in certain situations (e.g. Treating Pneumocystis. jiroveci pneumonia)

Trimethoprim is used for Rx community-acquired UTIs

73
Q

Resistance Mechanisms

A

Inactivation
Altered Target
Reduced Accumulation
Bypass

74
Q

Inactivation - B-Lactams

A

ß Lactamases are a major mechanism of resistance to ß Lactam antibiotics in Staphylococcus aureus and Gram Negative Bacilli (Coliforms).

NOT the mechanism of resistance in penicillin resistant Pneumococci and MRSA.

Penicillin resistance not reported in Group A (S. pyogenes), B, C, or G ß haemolytic Streptococci.

75
Q

Altered Targets: ß Lactams - MRSA

A

Methicillin Resistant Staphylococcus aureus (MRSA). (also fluclox resistant)

mecA gene encodes a novel PBP (2a).
Low affinity for binding ß Lactams.

Substitutes for the essential functions of high affinity PBPs at otherwise lethal concentrations of antibiotic.

76
Q

Altered Targets: ß Lactams - Strep Pneumo

A

Penicillin resistance is the result of the acquisition of a series of stepwise mutations in PBP genes.

Lower level resistance can be overcome by increasing the dose of penicillin used.

77
Q

Extended Spectrum ß Lactamases (ESBL)

A

Able to break down cephalosporins (cefotaxime, ceftazidime, cefuroxime) - enzymatic breakdown

Becoming more common in E. coli and Klebsiella species.

Treatment failures reported with ß Lactam/ ß Lactamase inhibitor combinations (eg. Augmentin/Tazocin).

78
Q

Altered Targets: Macrolides

A

Adenine-N6 methyltransferase modifies 23S rRNA

Modification reduces the binding of MLS antibiotics and results in resistance

Encoded by erm (erythromycin ribosome methylation) genes.

79
Q

CHOICE of the correct antimicrobial depends upon the

A

CHAOS

CHOICE of the correct antimicrobial depends upon the
HOST characteristics
ANTIMICROBIAL susceptibilities of the
ORGANISM itself and also the
SITE of the infection
  • Ideally narrow spectrum
  • Ideally bactericidal (vs static)
  • Ideally choice should be based upon a bacteriological diagnosis (otherwise, “best guess” based upon likely differential diagnosis)
  • Local sensitivities
  • Pt characteristics
  • Cost
80
Q

Host factors

A 
Age
Allergy
Genetics
Renal function
Hepatic function
81
Q

Organism Factors

A

Sensitivity (based on agar disc diffusion methods)

82
Q

(Preliminary) identification of the infecting ORGANISM

A

Gram stain:
CSF
Joint aspirate
Pus

Rapid antigen detection:
Immunofluorescence
PCR

83
Q

When ti switch from IV to PO

A

i.v. to p.o. switch is recommended in hospital for most infections if the patient has stabilised after 48 hours i.v. therapy

84
Q

Eagle Effect

A

paradoxically reduced antibacterial effect of penicillin at high doses, though recent usage generally refers to the relative lack of efficacy of beta-lactam antibacterial drugs on infections having large numbers of bacteria.

Penicillin is a bactericidal antibiotic that works by inhibiting cell wall synthesis but this synthesis only occurs when bacteria are actively replicating (or in the log phase of growth).
In cases of extremely high bacterial burden (such as with Group A Strep), bacteria may be in the stationary phase of growth.
In this instance since no bacteria are actively replicating (presumably due to nutrient restriction) penicillin has no activity.

85
Q

Staph Skin Infection - Rx

A

Fluclox
Pen allergic - doxy
MRSA - Vanc

86
Q

Pharyngitis - Rx

A

10 days benpen

87
Q

CAP (mild) - Rx

A

Amoxicillin

88
Q

CAP (severe) - Rx

A

Co-amox and clarithromycin

89
Q

HAP - Rx

A

cephalosporin; ciprofloxacin; piperacillin/tazobactam

If MRSA colonised/risk, consider addition of Vancomycin

Second most common cause of HAI.
Associated with highest mortality (23%).
Greatest risk associated with tracheal intubation and mechanical ventilation.

90
Q

Bacterial Meningitis - Rx

A

Ceftriaxone (+/- amoxycillin if Listeria likely)

Main pathogens:
N. Meningitidis
S. pneumoniae
+/- Listeria in the very young/elderly/immuno-compromised

Baby < 3 months : Cefotaxime PLUS Amoxicillin (to cover for listeriosis)

Note: Ceftriaxone not used in neonates as displaces bilirubin from albumin and because it can cause biliary sludging.

Neisseria meningitidis: Benzylpenicillin (high dose) or Ceftriaxone/Cefotaxime

91
Q

N. Meningitidis Penicillin Resistance

A
  • The mechanism of relative resistance to penicillin involves, at least in part, the production of altered forms of one of the penicillin-binding proteins.
  • Although treatment with penicillin is still effective against these relatively resistant strains, there is evidence that low-dose treatment regimens can fail.
  • Beta-Lactamase production in meningococci is extremely rare but has been reported
92
Q

Community Acquired UTI -Rx

A

3 days trimethoprim
Hospital acquired UTI - cephalexin/augmentin

Infected urinary catheter: change under gentamicin cover.

93
Q

C. diff colitis - Rx

A

STOP the offending antibiotic (usually a cephalosporin);

If severe, Rx with p.o. metronidazole;

If above fails, use p.o. vancomycin

94
Q

If no response within 48 hours, consider the following:

A
  • Does the patient really have a bacterial infection? (Have I collected the relevant cultures?)
  • Is there a persistent focus present (e.g. an infected vascular or urinary catheter)?
  • Is there a deep-seated collection (e.g. intra-abdominal) that requires drainage?
  • Could the patient have bacterial endocarditis?
  • Am I using the correct dose of the antimicrobial?
  • Is another infection present (esp consider Candida)?
95
Q

Disease Eradication - Prerequisites for Success

A

No animal reservoir

Antigenically stable pathogen with only one (or small number of) strains

No latent reservoir of infection and no integration of pathogen genetic material into host genome

Vaccine must induce a lasting and effective immune response

High coverage required for very contagious pathogens

96
Q

UK Measles and Rubella Elimination Strategy

A

Achieve and sustain ≥ 95% coverage with two doses of MMR vaccine in the routine childhood programme (<5 years old)

Achieve ≥ 95% coverage with two doses of MMR vaccine in older age cohorts through opportunistic and targeted catch-up (>5 years old)

Strengthen measles and rubella surveillance through rigorous case investigation and testing ≥80% of all suspected cases with an Oral Fluid Test(OFT)

Ensure easy access to high-quality, evidence-based information for health professionals and the public.

97
Q

Directly Acting Antivirals (DAAs)

A

Viruses encode specific proteins required for cell entry, genomic replication or transcription, assembly and release of progeny virions: Virally-encoded proteins, e.g. nucleic acid polymerases, proteases, integrase, CCR5, terminase

Small molecule inhibitors - directly-acting antivirals (DAAs) - can block production or action of the above and inhibit viral replication

98
Q

Directly acting antivirals can be boosted by

A

exogenous immunomodulators

Examples:	
Interferon Rx for HBV and HCV
IVIG for viral pneumonitis
imiquimod for HPV
steroids for HSE (?)
99
Q

Complications of VZV

A

Chicken pox pneumonitis

Shingles- post-herpetic neuralgia

100
Q

Prodrug

A

A prodrug is an inactive precursor of a drug, that is metabolized into the active form within the body.

101
Q

Acyclovir - MOA

A

Guanosine analogue

Further elongation of the chain is impossible because acyclovir lacks the 3’ hydroxyl group necessary for the insertion of an additional nucleotide

Selective activity of guanosine analogues:

  • Monophosphorylated by viral thymidine kinase (TK)
  • Affinity for herpesvirus DNA polymerase is 10- to 30- fold higher than for cellular (host) DNA polymerase for ACV-PPP
  • Selective activity means reduced drug toxicity
  • VZV 10x less sensitive (than HSV) so higher doses required
102
Q

BK Virus

A

Part of Polyomavirus family (related to JC virus)
Primary BK virus infection in childhood with minimal symptoms, but subsequent lifelong carriage in kidneys and urinary tract
Only becomes problematic in the immunocompromised:
- BMT: Haemorrhagic cystitis. Less commonly nephritis.
- Renal transplant:
BK nephritis and ureteric stenosis

Rx:
Bladder washouts
Reduce level of immunosuppression if possible
Cidofovir iv (+ probenicid) if significant morbidity
Intravesical cidofovir (5mg/kg/wk) an option if nephrotoxicity
Nephropathy - reduce level of immunosuppression, IVIG

Brincidofovir - oral prodrug of cidofovir but not licensed in UK

103
Q

Hep B approved drugs

A

Interferon (combined antiviral and immunomodulatory effects):
INF-a
Peg-INF a2-a

Nucleoside/nucelotide analogues (direct antiviral effect):
Tenofovir
Telbivudine
Entecavir
Lamivudine
104
Q

Hep C drugs

A

Combination of protease inhibitors, NS5A inhibitors and polymerase inhibitors (nucleoside and non-nucleoside)

Can use different DAAs spending on the HCV genotype.

glecaprevir/pibrentasvir (Maviret)
sofosbuvir/velpatasvir/voxaliprevir (Sovesi)
elbasvir/grazoprevir (Zepatier)

105
Q

Mechanisms of Antiviral Resistance

A

Diversity - Quasispecies, mutation / recombination

Selection - Replication (eg in the presence of suboptimal drug concentrations)

106
Q

Implications of of Antiviral Resistance

A

Treatment failure

Change to second line drugs - more toxic

Cross resistance (to prevent: Use potent drug regimens to achieve maximal suppression e.g. combo Rx/HAART, increase adherence to Rx)

107
Q

Antiviral Drug Resistance Assays

A

Genotypic: Sequencing / resistance mutations
Example: HIV drug resistance

Phenotypic:
Cell culture
Plaque reduction assay
Routinely used for HSV drug resistance testing

108
Q

HSV drug resistance (ACV)

A

Mutations usually in viral thymidine kinase (95%), and rarely in the viral DNA polymerase (5%)

The former mediates cross-resistance to GCV

Resistance strains selected out by drug treatment

Nearly always occurs in the context of immunosuppression – TK-deficient strains less virulent

Suspect if lesions fail to resolve despite adequate antiviral therapy

Diagnose with viral culture and phenotypic resistance test (plaque reduction assay) – time consuming and requires viable virus to be isolated

Treat ACV-resistant HSV with FOS or CDV

Virus tends to revert to wild type upon cessation of

109
Q

CMV drug resistance (GCV)

A

CMV genetic mutations:

  • In protein kinase gene (UL97) - most common
  • In the DNA polymerase gene (UL54) – rare
  • UL56 terminase gene (letermovir)

Most likely to occur in context of prolonged therapy in immunocompromised

Suspect if clinical or virological failure despite appropriate therapy and reduction of immune suppression

2nd line for CMV is foscarnet or cidofovir

110
Q

Immunoglobulin Preparations

A

Prophylactic:
- palivizumab (RSV)

Post-exposure prophylaxis:

  • Varicella zoster immunoglobulin - Immunocompromised / pregnant / neonates
  • Hepatitis B immunoglobulin - Unvaccinated recipient exposed to hepatitis B-positive source; Non-responder to vaccine exposed to source of positive or unknown status
  • Human Rabies Immunoglobulin (HRIG)

Therapeutic:

  • Human normal immunoglobulin (IVIG) as adjunctive treatment for viral pneumonitis (eg CMV)
  • Rituximab (anti-CD20) for EBV-driven PTLD

Liv Path (24 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions